Prognostic value of combined serum biomarkers in predicting outcomes in cervical cancer patients

Clinica Chimica Acta

Volumn 424, Issue , 2013, Pages 292-297

  Li, Juan ^a   Cheng, Hao ^b,c   Zhang, Pengjun ^a   Dong, Zhennan ^a   Tong, Hong li ^a   Jackie Han, Jing Dong ^b   Guo, Fei ^a   Tian, Ya ping ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Cox regression model; Kaplan Meier curve; Prognosis; Uterine cervical neoplasm

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBOHYDRATE ANTIGEN; CARBOHYDRATE ANTIGEN 125; CARBOHYDRATE ANTIGEN 153; CARBOHYDRATE ANTIGEN 199; CARBOHYDRATE ANTIGEN 21-1; CARBOHYDRATE ANTIGEN 724; CARCINOEMBRYONIC ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOREACTIVE FIBRONECTIN ALPHA; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NEURON SPECIFIC ENOLASE; SQUAMOUS CELL CARCINOMA ANTIGEN; SQUAMOUS CELL CARCINOMA ASSOCIATED ANTIGEN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SURVIVAL RATE; UTERINE CERVIX CANCER;

COX REGRESSION MODEL; KAPLAN-MEIER CURVE; PROGNOSIS; UTERINE CERVICAL NEOPLASM;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; HUMANS; MIDDLE AGED; MUCIN-1; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SERPINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; UTERINE CERVICAL NEOPLASMS;

EID: 84881249760     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.07.003     Document Type: Article

References (30)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156.
2. Kent A. HPV vaccination and testing. Reviews in obstetrics and gynecology 2010, 3:33-34.
3. Shi J.F., Qiao Y.L., Smith J.S., et al. Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia. Vaccine 2008, 26(Suppl. 12):M53-M59.
4. Klaes R., Woerner S.M., Ridder R., et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 1999, 59:6132-6136.
5. Zhao Y.B., Wang J.H., Chen X.X., Wu Y.Z., Wu Q. Values of three different preoperative regimens in comprehensive treatment for young patients with stage Ib2 cervical cancer. Asian Pacific journal of cancer prevention : APJCP 2012, 13:1487-1489.
6. Markowska J. [Tumor makrers in cervical cancer]. Ginekologia polska 2007; 78:715-718.
7. Perkins G.L., Slater E.D., Sanders G.K., Prichard J.G. Serum tumor markers. American family physician 2003, 68:1075-1082.
8. Liu C., Pan C., Shen J., Wang H., Yong L., Zhang R. Discrimination analysis of mass spectrometry proteomics for cervical cancer detection. Medical oncology 2011, 28(Suppl. 1):S553-S559.
9. Gadducci A., Tana R., Cosio S., Genazzani A.R. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol 2008, 66:10-20.
10. Abe A., Nakano T., Morita S., Oka K. Clinical evaluation of serum and immunohistochemical expression of SCC and CA19-9 in radiation therapy for cervical cancer. Anticancer Res 1999, 19:829-836.
11. Gaarenstroom K.N., Kenter G.G., Bonfrer J.M., et al. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?. Gynecol Oncol 2000, 77:164-170.
12. Molina R., Filella X., Auge J.M., et al. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA. Anticancer Res 2005, 25:1765-1771.
13. Suzuki Y., Nakano T., Ohno T., Abe A., Morita S., Tsujii H. Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy. Journal of cancer research and clinical oncology 2000, 126:332-336.
14. Peghini B.C., Abdalla D.R., Barcelos A.C., Teodoro L., Murta E.F., Michelin M.A. Local cytokine profiles of patients with cervical intraepithelial and invasive neoplasia. Human immunology 2012, 73:920-926.
15. Sharma A., Rajappa M., Saxena A., Sharma M. Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix. Int J Gynecol Cancer 2007, 17:879-885.
16. Sharma A., Rajappa M., Satyam A., Sharma M. Cytokines (TH1 and TH2) in patients with advanced cervical cancer undergoing neoadjuvant chemoradiation: correlation with treatment response. Int J Gynecol Cancer 2009, 19:1269-1275.
17. Roxburgh C.S., McMillan D.C. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future oncology 2010, 6:149-163.
18. McMillan D.C. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009, 12:223-226.
19. Tinga D.J., Bouma J., Aalders J.G. Patients with squamous cell versus adeno(squamous) carcinoma of the cervix, what factors determine the prognosis?. Int J Gynecol Cancer 1992, 2:83-91.
20. Takeda N., Sakuragi N., Takeda M., et al. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta obstetricia et gynecologica Scandinavica 2002, 81:1144-1151.
21. Molina R., Barak V., van Dalen A., et al. Tumor markers in breast cancer - European Group on Tumor Markers recommendations. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2005, 26:281-293.
22. Molina R., Auge J.M., Escudero J.M., et al. Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2008, 29:371-380.
23. Shetty A.V., Thirugnanam S., Dakshinamoorthy G., et al. 18alpha-glycyrrhetinic acid targets prostate cancer cells by down-regulating inflammation-related genes. Int J Oncol 2011, 39:635-640.
24. Park B.W., Oh J.W., Kim J.H., et al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Annals of oncology: official journal of the European Society for Medical Oncology//ESMO 2008, 19:675-681.
25. Davelaar E.M., van de Lande J., von Mensdorff-Pouilly S., Blankenstein M.A., Verheijen R.H., Kenemans P. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2008, 29:9-17.
26. Dowlati Y., Herrmann N., Swardfager W., et al. A meta-analysis of cytokines in major depression. Biological psychiatry 2010, 67:446-457.
27. Brynskov J., Foegh P., Pedersen G., et al. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 2002, 51:37-43.
28. Hidalgo K., Rojas I.G., Penissi A.B., Rudolph M.I. TNFalpha increases in vitro migration of human HPV18-positive SW756 cervical carcinoma cells. Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica et al. 2005, 29:303-311.
29. Pan F., Tian J., Ji C.S., et al. Association of TNF-alpha-308 and -238 polymorphisms with risk of cervical cancer: a meta-analysis. Asian Pacific journal of cancer prevention : APJCP 2012, 13:5777-5783.
30. Esajas M.D., Duk J.M., de Bruijn H.W., et al. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001, 19:3960-3966.